Brii Biosciences Management
Management criteria checks 1/4
Brii Biosciences' CEO is Zhi Hong, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is CN¥18.16M, comprised of 40.8% salary and 59.2% bonuses, including company stock and options. directly owns 4.5% of the company’s shares, worth €3.96M. The average tenure of the management team and the board of directors is 3 years and 2.2 years respectively.
Key information
Zhi Hong
Chief executive officer
CN¥18.2m
Total compensation
| CEO salary percentage | 40.8% |
| CEO tenure | 6.8yrs |
| CEO ownership | 4.5% |
| Management average tenure | 3yrs |
| Board average tenure | 2.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥265m |
| Mar 31 2024 | n/a | n/a | -CN¥220m |
| Dec 31 2023 | CN¥18m | CN¥7m | -CN¥175m |
| Sep 30 2023 | n/a | n/a | -CN¥251m |
| Jun 30 2023 | n/a | n/a | -CN¥327m |
| Mar 31 2023 | n/a | n/a | -CN¥405m |
| Dec 31 2022 | CN¥14m | CN¥7m | -CN¥484m |
| Sep 30 2022 | n/a | n/a | -CN¥1b |
| Jun 30 2022 | n/a | n/a | -CN¥2b |
| Mar 31 2022 | n/a | n/a | -CN¥3b |
| Dec 31 2021 | CN¥65m | CN¥37m | -CN¥4b |
| Sep 30 2021 | n/a | n/a | -CN¥4b |
| Jun 30 2021 | n/a | n/a | -CN¥4b |
| Mar 31 2021 | n/a | n/a | -CN¥3b |
| Dec 31 2020 | CN¥22m | CN¥5m | -CN¥1b |
| Dec 31 2019 | CN¥20m | CN¥4m | -CN¥521m |
Compensation vs Market: Zhi's total compensation ($USD2.51M) is above average for companies of similar size in the German market ($USD472.15K).
Compensation vs Earnings: Zhi's compensation has increased whilst the company is unprofitable.
CEO
Zhi Hong (60 yo)
6.8yrs
Tenure
CN¥18,158,000
Compensation
Dr. Zhi Hong, PhD, co-founded Brii Biosciences Limited in 2018 and serves as its Executive Chairman of the Board, Chief Executive Officer & Executive Director since 2018. Prior to starting Brii Bio, Dr. Ho...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 6.8yrs | CN¥18.16m | 4.5% € 4.0m | |
| Chief Financial & Strategy Officer | 3.6yrs | CN¥12.48m | 0.20% € 173.4k | |
| Chief Technology Officer | 2.3yrs | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Associate Director of Investor Relations | no data | no data | no data | |
| Chief People Officer & Head of Human Resources | 2.8yrs | no data | no data | |
| Head of Patient Advocacy | 3.2yrs | no data | no data | |
| Head of Discovery | no data | no data | no data | |
| Head of China Research & Development | 4.3yrs | no data | no data | |
| Chief Medical Officer | 4.1yrs | no data | no data | |
| Chief Business Officer | 2.3yrs | no data | no data | |
| Head of Central Nervous System Diseases Therapy Area Head | 2.3yrs | no data | no data |
3.0yrs
Average Tenure
55yo
Average Age
Experienced Management: 7SS's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 6.8yrs | CN¥18.16m | 4.5% € 4.0m | |
| Chief Financial & Strategy Officer | 2.2yrs | CN¥12.48m | 0.20% € 173.4k | |
| Independent Non-executive Director | no data | CN¥620.00k | 0.012% € 10.5k | |
| Independent Non-executive Director | no data | CN¥620.00k | 0.012% € 10.5k | |
| Independent Non-Executive Director | 2.2yrs | CN¥832.00k | 0.030% € 26.2k | |
| Independent Non-executive Director | no data | CN¥620.00k | 0.012% € 10.5k | |
| Independent Non-executive Director | no data | CN¥620.00k | 0.012% € 10.5k |
2.2yrs
Average Tenure
64yo
Average Age
Experienced Board: 7SS's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.